Cellectis — Regulatory Filings 2024

Aug 7, 2024

6-K 1 f6k_080624.htm FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: August 7, 2024

Commission File Number: 001-36891

Cellectis S.A. (Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):       

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):       

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. 

---

On August 7, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated August 7, 2024

Cellectis S.A.

This information included in this report on Form 6-K, excluding the Press Release filed as Exhibit 99.1, shall be deemed to be incorporated by reference in the Company's registration statements on Form F-3 (No. 333-265826) and Form S-8 (Nos. 333-204205, 333-214884, 333-222482, 333-227717, 333-258514, 333-267760, and 333-273777), to the extent not superseded by documents or reports subsequently filed.

Management Update

Cellectis S.A. (the “Company”) announced the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as Chief Medical Officer and member of the Company’s executive committee, effective immediately.

Prior to joining Cellectis, Dr. Kilcoyne was Chief Medical Officer and Head of Research and Development at Cellularity Inc. since October 2022, advancing their oncology allogeneic CAR-T and NK Cell therapy programs. Prior to this, Dr. Kilcoyne was Chief Medical Officer of Humanigen from April 2021 to September 2022. He has held numerous Oncology leadership roles across Research and Development, Medical Affairs, Commercial, Health Economic Outcome Research and Evidence Generation in both Big Pharma and Biotech, such as AstraZeneca (from June 2019 to April 2021) and Celgene (from November 2013 to June 2019). Dr. Kilcoyne holds an M.D. from Trinity College in Dublin. Dr. Kilcoyne was initially trained in Gynecological Oncology at the Hammersmith Hospital in London and subsequently in Public Health Medicine at Oxford. He holds a Masters in Public Health from the University of London. Dr. Kilcoyne then trained in pharmaceutical medicine and completed his M.B.A. from Warwick Business School.

Dr. Mark Frattini, the Company’s existing Chief Medical Officer, will leave his position with the Company, effective immediately, to pursue other opportunities.

EXHIBITS

Exhibit	Title
99.1	Press Release dated August 7, 2024

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Cellectis S.A.
	(Registrant)
Date: August 7, 2024	/s/ André Choulika
	André Choulika
	Chief Executive Officer